The enduring clinical benefits of anti-PD-1 and anti-PD-L1 therapies in NSCLC are well-established; however, as discussed, patients possessing EGFR mutations within NSCLC demonstrate a comparatively diminished response to such treatments (137). Here, PDCD1 is linked to non-small cell lung carcinoma.